Literature DB >> 10898412

Ten-year experience with early angioplasty in 759 patients with acute myocardial infarction.

F Bär1, J Vainer, J Stevenhagen, K Neven, R Aalbregt, T O Ophuis, V van Ommen, H de Swart, E de Muinck, W Dassen, H Wellens.   

Abstract

OBJECTIVES: How effective and safe is rescue percutaneous transluminal coronary angioplasty [PTCA] compared with primary PTCA, and is it cost effective?
BACKGROUND: In acute myocardial infarction (AMI), primary PTCA has been shown to be beneficial in terms of clinical outcome. In contrast, the value of rescue PTCA has not been established.
METHODS: In a retrospective analysis, we compared the angiographic and clinical outcomes of 317 consecutive patients who had rescue PTCA approximately 90 min after failed thrombolysis and 442 patients treated with primary PTCA. An estimation of interventional costs was compared with the strategies of primary and rescue PTCA or with the strategy of thrombolysis with rescue PTCA, when indicated.
RESULTS: Baseline characteristics between primary and rescue PTCA were comparable for most variables. Treatment delay was longer for patients who had rescue PTCA: 240 min. versus 195 min. Coronary patency after PTCA was comparable: 90.2% for rescue PTCA and 91.4% for primary PTCA (p = 0.67, power 71.9%). In-hospital mortality rates were 4.7% and 6.6%, respectively (p = 0.37). Also, the other complications were fairly similar during the in-hospital phase and during one-year follow-up. Predictors of death were age, infarct size, localization of AMI, failed PTCA and left main stem occlusion. The estimated interventional costs during one-year follow-up were $7,377 for primary PTCA and $8,246 for rescue PTCA: difference $869 (11.7%).
CONCLUSIONS: In this retrospective analysis of 759 patients with AMI, rescue angioplasty early after failed thrombolysis seems to be as effective and safe as primary PTCA. In the present evaluation, interventional costs of primary PTCA are less than those of rescue PTCA (p = 0.0001).

Entities:  

Mesh:

Year:  2000        PMID: 10898412     DOI: 10.1016/s0735-1097(00)00718-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  5 in total

1.  Transport for abciximab facilitated primary angioplasty versus on-site thrombolysis with a liberal rescue policy: the randomised Holland Infarction Study (HIS).

Authors:  Hendrik-Jan Dieker; Elvira V van Horssen; Ferry M R J Hersbach; Marc A Brouwer; Ad J van Boven; Arnoud W J van 't Hof; Wim R M Aengevaeren; Freek W A Verheugt; Frits W H M Bär
Journal:  J Thromb Thrombolysis       Date:  2006-08       Impact factor: 2.300

2.  One year results of the Middlesbrough early revascularisation to limit infarction (MERLIN) trial.

Authors:  A G C Sutton; P G Campbell; R Graham; D J A Price; J C Gray; E D Grech; J A Hall; A A Harcombe; R A Wright; R H Smith; J J Murphy; A Shyam-Sundar; M J Stewart; A Davies; N J Linker; M A de Belder
Journal:  Heart       Date:  2005-10       Impact factor: 5.994

3.  Prognostic significance of nonfatal myocardial reinfarction in survivors of a first infarction.

Authors:  R T van Domburg; J W Deckers; P F M M van Bergen; A J Azar; J J C Jonker; M L Simoons
Journal:  Neth Heart J       Date:  2001-08       Impact factor: 2.380

4.  A comparison of rescue and primary percutaneous coronary interventions for acute ST elevation myocardial infarction.

Authors:  M B Faslur Rahuman; Jayanthimala B Jayawardena; George R Francis; Niraj Mahboob; Wasantha Kumara A H T; Aruna Wijesinghe; Rashan Haniffa; Ranithrie Ariyapperuma; Abbyramy Paramanayakam; Pubudu A De Silva
Journal:  Indian Heart J       Date:  2017-03-06

5.  Accuracy of Post-thrombolysis ST-segment Reduction as an Adequate Reperfusion Predictor in the Pharmaco-Invasive Approach.

Authors:  Henrique Tria Bianco; Rui Povoa; Maria Cristina Izar; Braulio Luna Filho; Flavio Tocci Moreira; Edson Stefanini; Henrique Andrade Fonseca; Adriano Henrique Pereira Barbosa; Claudia Maria Rodrigues Alves; Adriano Mendes Caixeta; Iran Gonçalves; Pedro Ivo de Marqui Moraes; Renato Delascio Lopes; Angelo Amato Vincenzo de Paola; Dirceu Almeida; Valdir Ambrosio Moises; Francisco A H Fonseca
Journal:  Arq Bras Cardiol       Date:  2021-07       Impact factor: 2.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.